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Summary
The ability of mesenchymal stem cells (MSC) to suppress alloresponsiveness
is poorly understood. Herein, an allogeneic mixed lymphocyte response
was used as a model to investigate the mechanisms of MSC-mediated
immunomodulation. HumanMSC are demonstrated to express the immuno-
suppressive cytokines hepatocyte growth factor (HGF), interleukin (IL)-10
and transforming growth factor (TGF)-b1 at concentrations that suppress
alloresponses in vitro. MSC also express cyclooxygenase 1 and 2 and produce
prostaglandin E2 constitutively. Blocking studies with indomethacin con-
firmed that prostaglandins contribute to MSC-mediated allosuppression. The
proinflammatory cytokine interferon (IFN)-g did not ablate MSC inhibition
of alloantigen-driven proliferation but up-regulated HGF and TGF-b1. IFN-g
also induced expression of indoleamine 2,3, dioxygenase (IDO), involved in
tryptophan catabolism. Use of an antagonist, 1-methyl-L-tryptophan,
restored alloresponsiveness and confirmed an IDO contribution to IFN-g-
induced immunomodulation by MSC. Addition of the tryptophan catabolite
kynurenine to mixed lymphocyte reactions (MLR), blocked alloproliferation.
These findings support a model where IDO exerts its effect through the local
accumulation of tryptophan metabolites rather than through tryptophan
depletion. Taken together, these data demonstrate that soluble factors, or
products derived from MSC, modulate immune responses and suggest that
MSC create an immunosuppressivemicroenvironment capable of modulating
alloresponsiveness even in the presence of IFN-g.
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Introduction
Mesenchymal stem cells (MSC), first recognized by
Friedenstein and colleagues, are present at low numbers in
normal adult bone marrow [1]. They have the capacity for
controlled self-renewal and retain the potential to differen-
tiate into a variety of specialized cell types, including car-
tilage, bone, tendon, ligament, adipose tissue, neural
precursor cells, muscle and cardiomyocytes [2–4]. This
potential makes MSC attractive candidates for applications
in regenerative medicine. However, the use of autologous
MSC may be limited in a clinical setting, due to availability,
patient status and the demands required to make a person-
alized therapeutic approach feasible. Therefore, the possi-
bility of engrafting standardized, allogeneic MSC would be
very attractive therapeutically. The value of this approach
has been demonstrated by the use of allogeneic MSC to
treat children with osteogenesis imperfecta. Horwitz et al.
reported that allogeneic MSC delivery resulted in both
osteoblast engraftment and an increase in new bone forma-
tion, in the absence of marrow ablative chemotherapy [5].
Similar results have been observed in animal models
showing MSC to be beneficial for the repair of tissue
damage [3,6–8]. However, it is evident that the use of allo-
geneic, as opposed to autologous, stem cells in regenerative
medicine poses more profound problems of immune
rejection.
The capacity for MSC to escape immune recognition and
to suppress activation of T cells, both in vivo and in vitro, has
posed fundamental problems for immunologists in that
there is little apparent reason why evolution would retain
this property, given that allotransplantation is a recent
phenomenon. However, a number of recent studies have
suggested that allotransplantation of MSC may indeed be
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feasible [5,9,10]. Early clinical trials have demonstrated the
potential of MSC therapy and provide evidence supporting
tolerance to allogeneic MSC by recipients. Koc et al. showed
no evidence of alloreactive T cells, and no incidence of
graft-versus-host disease, when allogeneic MSC were infused
into patients with Hurler’s syndrome or metachromatic leu-
codystrophy [9]. Similarly, human MSC failed to elicit allo-
geneic T cell responses in mixed lymphocyte reactions
(MLR) even when major histocompatibility complex
(MHC) class II was up-regulated [11,12]. This effect is sup-
ported by observations that haploidentical MSC had striking
immunosuppressive effects when transplanted into a patient
with severe graft-versus-host disease [10]. Recently, work by
Aggarwal and Pittenger showed that MSC altered the phe-
notype of specific immune cells, providing evidence that
transplantation of allogeneic MSC is feasible [13]. Taken
together, these results suggest that MSC exert their effect
through the creation of a tolerogenic niche within the
recipient.
Although data showing the successful use of allogeneic
MSC in regenerative therapy is available, such approaches are
unlikely to be broadly acceptable until the exact molecular
mechanisms underlying the suppressive ability of MSC are
revealed in combination with clinical studies.At present these
mechanisms remain unclear. It is therefore a critical necessity
to establish the precise mechanisms by which MSC exert their
suppressive capabilities. Evidence from allogeneic co-cultures
or MLR has demonstrated that both cell–cell contact and
soluble factors contribute to the immunomodulatory func-
tion of MSC [14–17]. However, there are confounding data
regarding the mechanisms involved. Previously, we and
others have hypothesized that MSC retain features of the fetal
allograft and have proposed that soluble factors including
hepatocyte growth factor (HGF), interleukin (IL)-10, and the
expression of indoleamine 2,3-dioxygenase (IDO), are candi-
date factors utilized by MSC to elicit immunosuppressive
effects [18,19].
In the present study, we set out to determine the mecha-
nisms by which human MSC exert immunosuppressive activ-
ity using MLR involving allogeneic peripheral blood
mononuclear cells. The mechanism(s) underlying MSC-
mediated suppression of alloantigen-driven proliferation
were evaluated by assessing the role of different MSC-derived
soluble factors, examining their ability to suppress an alloge-
neic MLR and investigating the capacity to restore prolifera-
tion through neutralization or chemical antagonism.
Furthermore, as MSC may be required to retain immunosup-
pression in an inflammatory environment, the effect of the
proinflammatory cytokine interferon (IFN)-g on soluble
factor production by MSC was examined. Results indicate
that MSC have a distinctive immunosuppressive profile that
modulates immune cell proliferation and IFN-g does not
ablate but enhances that capacity. Taken together, these find-
ings support the use of allogeneic MSC in regenerative medi-
cine for inflamed tissue.
Materials and methods
Cell isolation, purification and culture
Human MSC were isolated and expanded from aspirates of
bone marrow from three different donors by direct plating,
as described previously [2,20]. Cultures were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal calf serum (FCS) and 1% penicillin/
streptomycin (Invitrogen-Gibco, Paisley, Scotland, UK).
Contamination in MSC populations is a key confounding
variable, therefore rigorous quality control was adopted to
ensure that MSC were not contaminated with haematopoi-
etic or other cell contaminants and that cells retained differ-
entiation capacity, as described previously [2,20]. In MSC
culture experiments, human epithelial (A549), which do not
secrete IL-10, transforming growth factor (TGF)-b, HGF or
fibroblast-like (HDF-a) cells that do not express COX iso-
forms, or culture supernatants as appropriate were typically
included as negative controls. Peripheral blood mononuclear
cells (PBMC) were isolated from MHC mismatched donors
by density gradient centrifugation, as described previously
[21], and isolated cells were cryopreserved for use in mixed
lymphocyte reactions. Study design and use of human mes-
enchymal stem cells was approved by the Bioethics Commit-
tees of the National University of Ireland Maynooth and the
National University of Ireland Galway.
MLR
Allogeneic mixed lymphocyte reactions were performed
with PBMC from MHC mismatched donors in flat-
bottomed 96-well plates (Nunc, Roskilde, Denmark) in a
total volume of 200 ml RPMI-1640 supplemented with 10%
heat-inactivated FCS and 1% penicillin/streptomycin
(Invitrogen-Gibco). Cells were cultured as follows: 1·5 ¥ 104
MSC were cultured for 24 h prior to PBMC addition. PBMC
from each donor were added at a concentration of 2 ¥ 105
per well. The ratio of MSC to responding lymphocytes was
selected after in-house optimization and reflects previous
studies in the field. In various MLR (with or without MSC)
cytokines, neutralizing antibodies, biochemical antagonists
or metabolites were added. These included: recombinant
IFN-g (R&D Systems, Abingdon, UK; 200 ng/ml); IL-10
(Immunotools, Friesoythe, Germany; 200 pg/ml), TGF-b1
(R&D Systems; 500 pg/ml), HGF (R&D Systems; 20 ng/ml);
polyclonal anti-human IL-10 (Peproptech, London, UK;
1–6 mg/ml), monoclonal anti-human TGF-b1 (R&D
Systems; 1–6 mg/ml), monoclonal anti-human HGF (R&D
Systems; 0·1–0·3 mg/ml); indomethacin (Sigma Aldrich,
Dublin, Ireland; 20 mM); acetyl sialic acid (Sigma Aldrich;
1 mM) or 1-methyl l-tryptophan (Sigma Aldrich; 10 mM); or
Kynurenine (Sigma Aldrich; 100 mM). Concentrations
chosen reflected those seen in MSC cultures or after in-house
optimization. For MLR containing MSC conditioned media,
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the supernatant used was taken from MSC that were
cultured alone for 24 h. After 5 days’ culture, 1 mCi
[3H]-thymidine was added to each well and incubated for a
further 6 h. Cells were then harvested and [3H]-thymidine
incorporation measured by liquid beta scintillation
counting. Proliferation was represented as the incorporated
radioactivity in counts per minute (cpm). Results are
expressed as the mean of triplicate values standard error
(s.e.).
Determination of kynurenine concentration in cell
culture
IDO activity was quantified by measuring kynurenine in
supernatant from MLR with or without MSC. The medium
was precipitated with 30% trichloroacetic acid (20% final
volume) and centrifuged at 10 000 g for 10 min. Kynurenine
was measured using reversed-phase high performance liquid
chromatography (HPLC) (SP8800, Spectra Physics,
Fremont, CA, USA). An RP18 column (250 ¥ 4 mm) with a
5-mM pore was used to separate samples and absorbance
measured at 360 nm. The mobile phase was a mixture of
5 mM aqueous zinc acetate solution and acetronitrile (Sigma
Aldrich) at a ratio of 92 : 8 (v/v) pH 4·9; a sample volume of
20 ml was used. The concentration of kynurenine was deter-
mined by comparison against standard kynurenine (Sigma-
Aldrich) solutions (0–100 mM). Chromatographic data was
processed using a SP4290 integrator (Spectra Physics).
Cytokine measurement
MSC were cultured in 24-well plates (Nunc) in a total of
0·5 ml DMEM culture media (2 ¥ 105/ml). Cells were har-
vested after 24 h and supernatants collected and assayed by
commercial enzyme immunoassay (EIA) for IL-10 (Immu-
notools), TGF-b1 (R&D Systems) or HGF (Immunotools;
recombinant HGF, R&D Systems). Characterization of
candidate cytokine mRNA expression by human MSC was
performed using reverse transcription–polymerase chain
reaction (RT–PCR). MSC were cultured as above for 6 h, or
in some cases 24 h. Total RNA was extracted from cells using
Tri-Reagent (Molecular Research Centre Inc, Cincinnati,
OH, USA) according to the manufacturer’s instructions.
Briefly, RNA was reverse-transcribed using Superscript II
(Invitrogen-gibco) to cDNA. cDNA was analysed for the
expression of human IL-10, HGF, TGF-a1, cyclooxygenase
(COX)-1, COX-2 and IDO mRNA by semiquantitative
RT–PCR. Primer sequences and annealing temperatures are
shown in Table 1.
Prostaglandin E2 (PGE2) determination
The PGE2 concentration from cultured MSC supernatant
was measured by a competitive enzyme immunoassay
(Cayman Chemical, Ann Arbor, MI, USA), according to the
manufacturer’s instructions. Briefly, this assay was accom-
plished by converting PGE2 metabolites into a single deriva-
tive measured by enzyme-linked immunosorbent assay
(ELISA). Inhibition of PGE2 was achieved using indometha-
cin (Sigma Aldrich), an anti-inflammatory agent that blocks
biosynthesis by inhibiting COX [22] at a previously opti-
mized concentration (20 mM, data not shown). MLR were
also performed with/without MSC and indomethacin
(20 mM) or the alternative inhibitor acetyl sialic acid
(Sigma Aldrich; 1 mM). Proliferation assays were performed
as above.
Statistical methods
The statistical significance was assessed using Prism3 soft-
ware (GraphPad Software, San Diego, CA, USA). Data were
presented as the mean s.e. Statistical analysis was per-
formed by paired t-test. A P-value of P < 0·05 (*), P < 0·01
(**) or P < 0·001 (***) were considered statistically
significant.
Table 1. Sequences of primers employed for reverse transcription–polymerase chain reaction (RT–PCR) studies.
Target Primer sequence1
Product
size (bp)
Anneal
temp °C
TGF-b1 F 5′-CAGATCCTGTCCAAGCTG-3′ 270 54·8
R 5′-TCGGAGCTCTGATGTGTT-3′
HGF F 5′-ATGCATCCAAGGTCAAGGAG-3′ 349 56
R 5′-TTCCATGTTCTTGTCCCACA-3′
IL-10 F 5′-ATCCAAGACAACACTACTAA-3′ 588 55
R 5′-TAAATATCCTCAAAGTTCC-3′
IDO F 5′-CGCTGTTGGAAATAGCTTC-3′ 234 55
R 5′-CAGGACGTCAAAGCACTGAA-3′
COX 1 F 5′-GAGTTTGTCAATGCCACCT-3′ 215 58·5
R 5′-CAACTGCTTCTTCCCTTTG-3′
COX 2 F 5′-TCCTTGCTGTTCCCACCCATG-3′ 847 55·5
R 5′-CATCATCAGACCAGGCACCAG-3′
1Forward (F) and reverse (R) primers used to detect mRNA expression for the targets described. TGF: transforming growth factor; HGF: hepatocyte
growth factor; IL: interleukin; IDO: indoleamine 2,3, dioxygenase; COX: cyclooxygenase.
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Results
Human MSC constitutively express HGF, IL-10 and
TGF-b1 at immunosuppressive concentrations
In order to investigate the contribution of soluble factors to
immunosuppression, human MSC were examined for their
ability to modulate a mixed lymphocyte reaction (MLR), a
well-characterized model of allogeneic interaction. MSC
were co-cultured with PBMC from two MHC mismatched
donors. In line with previous observations, MSC signifi-
cantly reduced proliferation of responder PBMC (Fig. 1).
However, there is controversy as to whether the suppressive
effects of MSC are contact-dependent or mediated through
the release of soluble factors [14–17,23,24]. Therefore,
two-way MLR were performed supplemented by condi-
tioned media from 24-h MSC cultured alone. MSC-
derived supernatant suppressed proliferation significantly
(Fig. 1) (P < 0·05), suggesting that soluble factors were
involved in mediating inhibition of T cell proliferation.
However, suppression was less than when cell–cell contact
between MSC and effector cells was permitted, suggesting
that both contact-dependent and -independent mecha-
nisms operate.
In order to dissect these effects, MSC cultures were exam-
ined for the production of three potent immunomodulatory
mediators. IL-10 and TGF-b1 are known immunosuppressive
cytokines that have the ability to inhibit proinflammatory
cytokine secretion by antigen-presenting cells (APCs) and
both are involved in the induction of regulatory T cells
[25,26]. Similarly, HGF, a cytokine with anti-apoptotic and
haematopoietic activity, is emerging as a potent immuno-
modulator [27]. Cultured human MSC constitutively
expressed mRNA for HGF, IL-10 and TGF-b1 (Fig. 2a–c), and
all three cytokines could be detected by EIA in supernatants
from 24-h cultures by cytokine-specific EIA (Fig. 2d–f).
Human IL-10, TGF-b1 and HGF are known to have
immunomodulatory properties; however, the activity of
these cytokines is concentration-dependent and there is a
danger of interpreting data based on observations relating
to cytokine concentrations that are not physiologically
relevant. Therefore, the effect of these cytokines on alloge-
neic MLR was examined using concentrations that reflected
those seen in MSC culture and which were achievable in vivo
(Fig. 2). All three cytokines reduced proliferation repeatedly
(Fig. 3), suggesting that these cytokines contribute to MSC-
mediated suppression through soluble factors.
To clarify whether these soluble factors were responsible
for MSC-mediated suppression, neutralizing monoclonal
antibodies directed against IL-10, TGF-b1 and HGF were
added into an MLR containing MSC. In these experiments
concentrations of antibody were chosen to reflect the
optimium range that effectively neutralized concentrations
greater than the amount of cytokine released by MSC as seen
in Fig. 2. Consistent with other findings [12,24], neutraliza-
tion of these soluble factors either alone or in combination
failed to prevent MSC-mediated suppression, suggesting that
there is either redundancy in the mechanisms of immuno-
suppression employed by MSC or that other mechanisms
take precedence in this function.
Human MSC constitutively express COX-1, COX-2
and PGE2
Prostaglandins are lipid mediators known to suppress T cells
[28]. These mediators are derived from the conversion of
arachidonic acid to prostaglandins by isoforms of COX [28].
Therefore, the expression of COX-1 and COX-2 by unstimu-
lated MSC were examined. mRNA for both COX-1 and
COX-2 were expressed constitutively by MSC detectable by
RT–PCR (Fig. 4a), and significant levels of PGE2 were
detected in supernatants from MSC cultures (Fig. 4b). To
determine whether PGE2 produced by MSC could account for
the inhibition of T cell proliferation, the effect of blocking
COX activity was examined. Indomethacin is a non-steroidal
anti-inflammatory drug that blocks prostaglandin biosynthe-
sis by inhibiting cyclooxygenase [22]. Figure 4b shows that
PGE2 production was decreased dramatically when MSC were
treated with indomethacin. It was therefore necessary to
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Fig. 1. Mesenchymal stem cells (MSC) suppress alloantigen-driven
proliferation. MSC were co-cultured with peripheral blood
mononuclear cells (PBMC) from major histocompatibility complex
(MHC) mismatched donors (P1 or P2) for 96 h and
alloantigen-driven proliferation measured by [3H]-thymidine
incorporation expressed as mean counts per minute
(cpm) standard error. Significantly reduced proliferation by
responder PBMC (*P = 0·012) was determined by paired t-test
analysis. Conditioned media (MSC s/n) obtained from 24-h MSC
cultures suppressed alloantigen-driven proliferation (*P = 0·027).
MSC or PBMC cultured alone are shown for comparison. Results are
representative of three independent experiments each performed in
triplicate. No significant loss of viability or induction of apoptosis was
detected in this or subsequent experiments.
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determine whether blocking PGE2 synthesis interfered with
MSC-mediated suppression. Figure 4c shows that allogeneic
proliferation was significantly restored once PGE2 production
was prevented in MSC co-culture. Similarly, addition of
aspirin (acetyl sialic acid), an alternative COX inhibitor,
showed a similar effect [29]. Taken together, these results
demonstrate a functional role for PGE2 in suppression medi-
ated by unstimulated MSC through soluble factors.
IFN-g does not ablate MSC inhibition of T cell
proliferation but induces high-levels of HGF and
TGF-b1 expression
For clinical utility, allogeneic MSC must remain immuno-
suppressive in an inflamed environment. Therefore, the
effect of IFN-g stimulation on MSC-mediated inhibition of
alloantigen-driven proliferation was examined. IFN-g did
not ablate the immunosuppressive effect of MSC in MLR;
rather, it suppressed alloantigen-induced T cell proliferation.
Figure 5 shows that the suppression of alloresponses, medi-
ated by MSC, was not reversed by IFN-g stimulation.
As IFN-g exerts potent immunomodulatory and anti-
proliferative effects both in vitro and in vivo [30,31], the
effects of IFN-g on MSC cultures were examined. Surpris-
ingly, IFN-g stimulation resulted in a significant increase in
MSC production of HGF and TGF-b1, and no significant
reduction in the high levels of IL-10 (Fig. 6a–c). These find-
ings are consistent with a model in which MSC can be acti-
vated by inflammatory signals and that such activation
supports potent immunosuppressive activity.
IFN-g-induced expression of IDO by MSC contributes
to immunomodulation
Expression of the tryptophan degrading enzyme IDO has
been documented as playing a role in the suppression of T
cell activity at the feto–maternal interface [32,33]. Recently,
we and others proposed that MSC retain features of this
frequent form of allograft-mediated immune modulation
[19,34]. The expression of IDO by MSC was therefore
investigated. RT–PCR demonstrated that human MSC do
not constitutively express IDO (Fig. 6d). However IFN-g
stimulation of MSC induced enzyme expression detectable
by RT–PCR (Fig. 6d). Again, the presence of mRNA need not
correlate with protein or functional activity, therefore a
chemical antagonist, 1 methyl l-tryptophan (mLT), was
introduced to MLR containing MSC. Addition of mLT
restored proliferation (Fig. 7a), suggesting that IDO activity
contributes to IFN-g-mediated MSC immunomodulation.
Previously, we and others have proposed that local tryp-
tophan depletion may lead to a ‘tryptophan desert’, a condi-
tion that is putatively suppressive for T cell priming [19,35].
However, an alternative possibility was that tryptophan
depletion was a surrogate marker and that the local accumu-
lation of tryptophan metabolites was acting as the direct
immunomodulator. Consequently the tryptophan metabo-
lite kynurenine was added to MLR in the absence of MSC.
Cultures showed no apoptosis or decreased viability (data
not shown); however, kynurenine blocked alloanti-
gen-driven proliferation (Fig. 7b). Thus IFN-g-mediated
suppression of alloresponsiveness by MSC involves IDO-
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Fig. 2. Mesenchymal stem cell (MSC) production of immunomodulatory mediators determined by reverse transcription–polymerase chain reaction
(RT–PCR) (a–c) and enzyme immunoassay (EIA) (d–f). mRNA was isolated from 6-h cultures of unstimulated MSC and subjected to
semiquantitive reverse transcription–polymerase chain reaction (RT–PCR) as detailed in Methods for hepatocyte growth factor (HGF) (a),
interleukin (IL)-10 (b) and transforming growth factor (TGF)-b1 (c). As human results may show variability, MSC derived from three separate
donors (a–c: MSC 1, 2, 3) are shown. Supernatants from parallel cultures were also examined at 24 h for HGF (d), IL-10 (e) and TGF-b1 (f) protein
expression by EIA. – indicates mRNA (a–c) from 6-h epithelial (A549) non-cytokine-secreting cell cultures or 24-h culture supernatants (d–f) as
negative controls. EIA results are representative of three independent experiments using MSC from donor 1. EIA determinations were each
performed in triplicate and expressed as mean concentration standard error.
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mediated mechanisms, but this may be driven by the accu-
mulation of local kynurenine rather than tryptophan
depletion. Ideally, antibody neutralization or siRNA studies
would confirm these findings; however, the small size of
kynurenine and its position as a metabolic degradation
product preclude these approaches. However, in addition to
the metabolic inhibitor study (Fig. 7a), a testable prediction
from this hypothesis was that increased levels of kynurenine
would be observed in MLR that contained MSC; to test this
possibility, kynurenine concentration was measured by
HPLC from different cultures with or without MSC. Consis-
tent with the hypothesis above, Fig. 7c shows that kynure-
nine did accumulate when MLR were performed in the
presence of MSC.
Discussion
The mechanisms through which human mesenchymal stem
cells suppress alloresponses are poorly understood. This
study, using an MLR model, does not exclude a role for
cell-contact-dependent mechanisms, but clarifies how MSC
contribute to conditioning an immunosuppressive milieu
through cytokine secretion and expression of enzymatic
pathways associated with immune modulation. Human
MSC constitutively express levels of HGF, IL-10 and TGF-b1
that can modulate alloresponses. MSC are also shown to
constitutively express COX-1 and -2. Antagonists of prostag-
landin biosynthesis significantly reduced the suppressive
activity of MSC, supporting a role for prostaglandins in this
Fig. 3. Immunosuppressive cytokines reduced
alloantigen-driven proliferation but could not
be reversed by neutralizing these factors. (a)
mixed lymphocyte reactions (MLR) were
performed with major histocompatibility
complex (MHC) mismatched peripheral blood
mononuclear cells (PBMC) (P1 and P2) but not
mesenchymal stem cells (MSC). Selected
cultures also contained recombinant human
hepatocyte growth factor (HGF) (20 ng/ml),
interleukin (IL)-10 (200 pg/ml) or transforming
growth factor (TGF)-b1 (500 pg/ml). Cytokine
concentrations were selected as comparable to
that observed in Fig. 2. HGF, IL-10 and TGF-b1
significantly decreased alloantigen-driven
proliferation (*P = 0·04, P = 0·044 and
P = 0·018, respectively). In blocking studies (b)
neutralizing antibodies against these cytokines
(anti-HGF, 0·1–0·3 mg/ml; anti-TGF-b1,
1–6 mg/ml; anti-IL-10, 1–6 mg/ml) alone or in
combination were added to MLR from MHC
mismatched donors as above. Blocking any one
of these factors alone or in combination did not
reverse the inhibitory effect of MSC.
Proliferation by responder PBMC are expressed
as mean counts per minute standard error.
Results are representative of at least three
independent experiments, each performed in
triplicate.
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effect. Exposure to IFN-g did not ablate MSC inhibition
of T cell proliferation but induced expression of HGF
and TGF-b1 at concentrations that suppressed
alloresponsiveness. IDO was not expressed constitutively by
MSC but could be induced by IFN-g, and expression con-
tributed to immunomodulation as demonstrated by use of
an antagonist. However, addition of kynurenine to MSC cul-
tures also blocked allodriven proliferation, suggesting that
immunosuppression may be mediated through the local
accumulation of tryptophan metabolites rather than tryp-
tophan depletion. The observation of increased kynurenine
concentration in MLR containing MSC supported this
hypothesis. Taken together, these results demonstrate that
MSC could be activated by inflammatory signals and that
such activation supported up-regulation of potent immuno-
suppressive activity consistent with the creation of an immu-
nosuppressive microenvironment through soluble factors.
The mechanisms by which MSC suppress alloresponsive-
ness has been the subject of intense recent research
[18,19,34,36]. From an evolutionary standpoint, the capacity
of MSC to perform such a function is counterintuitive.
However, we and others have suggested recently that MSC
retain the immunomodulatory properties of the fetal
allograft [18,34]. This concept is intriguing, given that both
entities have to retain the capacity for controlled cell division
and multi-potent differentiation. Thus, the reason that MSC
possess such immunomodulatory capacity may be that it is a
retained attribute of mesenchymal ‘stemness’ and differen-
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Fig. 4. Human mesenchymal stem cells (MSC) modulate alloresponses through prostaglandin production. (a) Expression of cyclooxygenase
(COX)-1 and COX-2 mRNA by MSC or control prostaglandin E (PGE) non-producing fibroblast (–) cells was determined by reverse
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detected in supernatants sampled from 24-h cultures of MSC but antagonized by indomethacin, as determined by specific enzyme immunoassay
(EIA). (c) MSC were co-cultured in mixed lymphocyte reactions (MLR) from major histocompatibility complex (MHC) mismatched donors (P1 or
P2) as in Fig. 1, but additionally cultures were established containing either indomethacin (20 mM) or acetyl sialic acid (aspirin, 1 mM). PGE2
inhibition by either indomethacin or aspirin significantly restored alloantigen driven proliferation (*P = 0·015 and P =0·0158, respectively).
Proliferation by responder peripheral blood mononuclear cells (PBMC) are expressed as mean counts per minute standard error. Results are
representative of at least three experiments, each performed in triplicate.
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Fig. 5. Interferon (IFN)-g does not prevent mesenchymal stem cells
(MSC) suppression of alloresponsiveness. Mixed lymphocyte reactions
(MLR) were performed in the presence or absence of MSC as
described in the legend to Fig. 1. MSC significantly suppress
alloantigen-driven proliferation (**P = 0·0031). Additionally selected
wells contained interferon (IFN)-g (200 ng/ml) for the duration of the
cultures. A significant decrease in proliferation by responder
peripheral blood mononuclear cells (PBMC) was observed even in the
presence of IFN-g (**P = 0·0051). Proliferation by responder PBMC
are expressed as mean counts per minute standard error. Results are
representative of three independent experiments, each performed in
triplicate.
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tiation capacity. It is known that the study of MSC is con-
founded by species and methodological differences, and
different groups have reported differences in immunomodu-
latory capacity [6,12–17,23]. Despite these differences, there
is agreement that MSC use a surprising array of mechanisms
to avoid deletion by the mismatched host [18,19].
There is further conflicting opinion regarding the contri-
bution from cell-contact-dependent and -independent
mechanisms to suppression [13–17]. While this study has
focused on the soluble factors from MSC that could condi-
tion the cellular microenvironment, our antagonist studies
suggest that contact-dependent mechanisms are also
involved. A dual mechanism that involves both contribu-
tions is reminiscent of previous scientific debates regarding
the mechanisms by which CD4+ T cells provide help for B
cell production of antibody [37,38]. That process is now
known to require contact-dependent and -independent
mechanisms operating in concert [39]. The data provided
herein are consistent with MSC mediating suppression via
both mechanisms, albeit through different soluble mediators
and ligand–receptor interactions.
This study demonstrates that a well-characterized human
MSC population constitutively secretes the immunomodu-
latory cytokines HGF, IL-10, TGF-b1 at concentrations that
can suppress alloresponsiveness (Figs 2 and 3). Interestingly,
comparison of the mechanisms operating at the materno–
fetal interface show striking similarities, where HGF, IL-10,
TGF-b1 play an immunomodulatory role that serves to con-
tribute to tolerance of the fetal allograft [18]. The observa-
tion that MSC supernatant suppressed MLR indicates that
cell–cell contact is not an absolute requirement for
suppression. In contrast, Maitra et al. observed significant
inhibition of MLR only when conditioned medium from
MSC and unrelated lymphocytes was used, suggesting that
an MSC–lymphocyte interaction results in the release of
inhibitory mediators either by MSC or lymphocytes [40].
Both data are consistent with soluble factor production
requiring an as-yet unidentified activation event. However,
as lymphocytes were not present in the system to develop
conditioned medium in this work, the findings herein
suggest that it is MSC-derived factors that are mediating
suppression. Similarly, animal studies by Krampera et al. and
Augello et al. stress the significance of cell–cell contact for
specific inhibition of T cell activation [16,41]. However,
Augello et al. showed that soluble factors are involved in
suppression of B cells [41].
The present study found that the immunosuppressive
effect mediated by MSC is not reversed by neutralizing IL-10,
Fig. 6. Interferon (IFN)-g increases expression
of hepatocyte growth factor (HGF) and
transforming growth factor (TGF)-b1 and
induces indoleamine 2,3, dioxygenase (IDO).
Supernatants from 24-h cultures of
mesenchymal stem cells (MSC) in the absence
or presence of IFN-g (200 ng/ml) were also
examined for HGF (a), interleukin (IL)-10 (b)
and transforming growth factor (TGF)-b1 (c);
24-h cultures of unstimulated or
IFN-g-stimulated MSC were lysed and assayed
by semiquantitive transcription–polymerase
chain reaction (RT–PCR) for IDO mRNA
expression (d) as detailed in Methods. IFN-g
significantly increased HGF (**P = 0·0097) and
TGF-b1 (***P = 0·0008) and did not reduce
IL-10 expression following stimulation
(P = 0·5). Enzyme immunoassay (EIA) results
are expressed as mean counts per
minute standard error and are representative
of at least three independent experiments, each
performed in triplicate.
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HGF and/or TGF-b1; however, a role for their involvement
cannot be ruled out completely. There is a possibility that
these factors play a supporting but redundant role as immu-
nosuppressive mediators. Previous studies have suggested
that HGF played a role in the acceptance of allogeneic grafts.
Although Le Blanc et al. did not detect HGF in MSC
co-cultures [24], Di Nicola et al. suggest that HGF works in
synergy with TGF-b1 to resist T cell recognition [14]. Simul-
taneous neutralization of HGF and TGF-b1 in the latter study
restored T cell proliferation; however, even using combina-
tions of neutralizing antibodies, this effect was not observed
herein. This discrepancy may be explained by differences in
MSC and MLR populations. Di Nicola et al. used CD2+ sepa-
rated allogeneic cells cultured at a ratio of 1 : 1 MSC : PBMC.
Nevertheless, the possibility of the involvement of these
soluble factors is not excluded by our findings; rather we
propose that they have a subsidiary or redundant role.
This study clarifies the role of prostaglandins in MSC-
mediated immunomodulation. In humans, expression of
COX-1 is generally considered to be widespread, whereas
COX-2 expression is more restricted [28]. Here, we confirm
that human MSC express both COX-1 and -2. By blocking
these isoforms, we have shown effectively that PGE2 has a
role in mediating suppression (Fig. 4c). Although this con-
flicts with some studies suggesting that PGE2 is not a signifi-
cant component of suppression [12,23], Aggarawal and
Pittenger have shown that inhibition of PGE2 ablated MSC-
mediated immunosuppressive effects on T cells [13]. This
finding has two important implications. First, it demon-
strates another parallel between the tolerance of the fetal
allograft and MSC, as PGE2 performs both physiological and
developmental functions during pregnancy with an immu-
nomodulatory role that protects the fetal allograft [42,43].
The second implication is of potential clinical importance
and has received little attention. MSC have been proposed as
potential therapeutic agents in ischaemic heart disease;
however, many of these patients will be on pre-existing
medications which may influence PGE2 expression [44,45].
Caution will need to be taken in the use of allogeneic MSC in
such situations to ensure that pre-existing therapies do not
interfere with MSC capacity to suppress alloreactivity.
A key question that will decide the utility of clinical use of
MSC for regenerative medicine centres on whether MSC
retain their immunomodulatory capacity in an inflamed
environment. Very recent work by Krampera et al. suggests
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Fig. 7. Indoleamine 2,3, dioxygenase (IDO) plays a role in
mesenchymal stem cells (MSC)-mediated suppression of
allo-responsiveness. Mixed lymphocyte reactions (MLR) were
performed with mismatched donors (P1 and P2), as described in the
legend to Fig. 1. Additionally, selected wells were treated with the IDO
antagonist, 1-methyl l-tryptophan (mLT) (10 mM) (a) or with MSC
replaced by the tryptophan breakdown product kynurenine (100 mM)
(b). mLT significantly restored proliferation (a; *P = 0·047);
conversely, addition of exogenous kynurenine significantly reduced
allo-driven proliferation (b; **P = 0·0084). Kynurenine also
accumulated in MLR containing MSC (c). Kynurenine concentration
in supernatant from MLR with or without MSC was determined by
high performance liquid chromatography (HPLC) as described in
Methods. Kynurenine was significantly increased in MLR performed
in the presence of MSC (*P = 0·022), peripheral blood mononuclear
cells (PBMC) and MSC cultures are shown for comparison. Results
are representative of three independent experiments, expressed as
mean standard error, each performed in triplicate.

Mesenchymal stem cells avoid allorejection
361© 2007 The Author(s)
Journal compilation © 2007 British Society for Immunology, Clinical and Experimental Immunology, 149: 353–363
that IFN-g produced upon T cell activation contributes to
MSC suppressive activity [46]. The present study shows that
addition of the proinflammatory cytokine IFN-g, even at a
high concentration, does not ablate MSC immunosuppres-
sive activity. More importantly, we demonstrate that IFN-g
stimulation of MSC enhances the secretion of the immuno-
suppressive mediators, HGF and TGF-b1, which can poten-
tially inhibit T cell proliferation (Fig. 2), supporting a role
for IFN-g, and in line with studies showing that MSC
exposed to IFN-g fail to up-regulate MHC class II and do not
elicit alloreactive lymphocyte responses [11].
Tissue damage (presumably requiring the recruitment of
stem cells/induction of repair mechanisms) and inflamma-
tion are coincident and co-localized processes. It is therefore
not surprising that MSC can be activated by inflammatory
signals and that such activation should support
up-regulation of potent immunosuppressive activity. The
current study therefore reinforces the potential use of MSC
in the clinical setting where inflammation is a feature, but
where therapeutic prostaglandin inhibition is not an under-
lying requirement.
The immunological role of IDO, a tryptophan cataboliz-
ing enzyme [35], has also been the subject of recent debate.
IDO expression in the syncytiotrophoblast contributes to
the tolerance of the fetal allograft, where expression is
thought to deplete the local environment of l-tryptophan,
an essential amino acid for cell growth [47]. Previously, we
and others have suggested that IDO expression leads to the
formation of a ‘tryptophan desert’, a microenvironment in
which tryptophan is depleted, that modulates T cell func-
tion, and during infection impairs microbial activity
[19,48,49]. However, our results presented herein refine that
model. We show that IFN-g up-regulates IDO expression by
MSC. Response elements for IFN-g have been identified in
the human IDO promoter and shown to be essential for
induction of reporter gene expression in vitro [50]. Two
IFN-stimulated response elements (ISREs) and an IFN-g-
activated site (GAS) element are found in the 5′-flanking
region of the IDO gene, supporting a role for IFN-g in regu-
lating IDO [50]. IDO expression by activated MSC may play
a role in allo-MSC acceptance and could represent a novel
means of immunoregulation for both MSC and the fetal
allograft. IDO involvement has been suggested by studies
showing restoration of T cell proliferation by addition of
tryptophan to an MLR [51]. In the current study, we extend
this further to show that an IDO antagonist, 1-methyl
l-tryptophan, ablates MSC immunomodulation, indicating
the IDO functional activity is a mechanism contributing to
suppression. In addition to this, we show that inhibition of
T cell proliferation may be mediated through the accumu-
lation of kynurenine, a tryptophan breakdown product [52].
Furthermore, we show that kynurenine concentration
increases in MSC-suppressed MLR consistent with this
hypothesis. This study may resolve confounding observa-
tions concerning the role of IDO in suppression using
tryptophan supplementation [12]. IDO may exert its effect
not through depletion (the creation of a ‘tryptophan
desert’), but rather through local accumulation of kynure-
nine, a product of tryptophan catabolism.
In conclusion, we demonstrate that MSC secrete factors
consistent with the creation of an immunosuppressive
milieu or microenvironment. The similarity to the materno–
fetal interaction is striking. The carriage of the fetal allograft
requires a range of co-ordinated immunomodulatory activi-
ties involving cell–cell contact and soluble factors. The data
herein are consistent with MSC retaining not just early life
features of differentiation, multipotency and controlled
renewal, but also mechanisms of immunomodulation asso-
ciated normally with the survival of the fetal allograft.
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